Ultime notizie sulla terapia: Un farmaco anti-infiammatorio riduce eventi cardiovascolari maggiori
Inflammation expert opinionsAug. 27, 2017 - ESC 2017, Barcelona, Spain
Il prof. Raffaele De Caterina spiega perché CANTOS è uno studio clinico importante. E’ il primo studio clinico che dimostra che un farmaco anti-infiammatorio influenza favorevolmente importanti eventi cardiovascolari, e pertanto può diventare una terapia da inserire nell’armamentario terapeutico in aggiunto agli attuali trattamenti.
The CANTOS trial is the first in a series of trials that test the hypothesis that inhibiting inflammation can lower residual CV risk. The results of this trial indeed confirm this hypothesis, suggesting that from now on, targeting inflammation may need to be considered in patients on lipid-lowering therapy with residual inflammatory CV risk.
These inflammation expert opinion videos are aimed to provide guidance and perspectives on the implications of the CANTOS trial and other trials addressing inflammation in CVD. These expert views may help translate scientific findings to future clinical practice, by improving personalized CV risk management.
This recording was developed under auspices of PACE-cme.
The views expressed in this recording are those of the presenter and do not necessarily reflect the views of PACE-cme.
Prof. Raffaele De Caterina, MD, Professor of Cardiology, G. d’Annunzio University in Chieti, Italy
Funding to produce this expert opinion was provided by an unrestricted educational grant from Novartis.